⚛️ What Is PT‑141? A Peptide Studied for Neurological and Receptor Signaling
Share
What Is PT‑141?
PT‑141, also known as Bremelanotide, is a synthetic peptide that is studied as an analog of alpha-melanocyte-stimulating hormone (α‑MSH). It interacts with melanocortin receptors, primarily MC3R and MC4R, which are involved in neuroendocrine signaling, inflammation, and energy regulation.
Originally derived from research on melanin pathways, PT‑141 has since become a focus in studies related to central nervous system function, including how signals are processed in the brain related to mood, appetite, and behavior.
Explore PT‑141 at NovaGene Labs →
Why Do Researchers Study PT‑141?
PT‑141 is studied for its potential role in influencing neurological signaling pathways, particularly those connected to:
- Melanocortin receptor activity (MC3R and MC4R)
- Hypothalamic function
- Appetite and energy balance regulation
- Neuroimmune communication
- Behavioral research models
Researchers have explored PT‑141 in preclinical environments to observe how melanocortin receptor modulation affects mood, social behavior, and stress responses.
Mechanism of Action in Research
Unlike many peptides that act peripherally, PT‑141 is primarily studied for its central activity—meaning its effect on the brain and neural circuits. In research settings, PT‑141 is shown to bind with high affinity to MC4R, a receptor expressed in the hypothalamus, a key brain region that regulates homeostasis.
In cellular and animal models, PT‑141 has been observed to:
- Trigger neural signaling cascades
- Modulate neuropeptides linked to motivation and stress
- Affect pathways associated with inflammation and immune regulation
Why Choose NovaGene Labs?
NovaGene Labs offers PT‑141 in formats designed for laboratory use in preclinical and molecular research.
Our PT‑141 is:
- Synthesized to high purity specifications
- Offered in lyophilized and solution formats
- Cold-shipped only when pre-mixed (lyophilized products are not shipped cold)
- Clearly labeled for Research Use Only
View PT‑141 Research Compound →
📚 References
- Hadley, M. E., & Haskell-Luevano, C. (1999). The melanocortin system: A model for the development of peptide agonists and antagonists. Peptides, 20(4), 445–460.
- Hruby, V. J., & Wilkes, B. C. (2004). Peptide analogs as tools in receptor pharmacology. Current Opinion in Chemical Biology, 8(4), 379–385.
- Kask, A. et al. (2000). Central administration of melanocortin agonist influences behaviors associated with energy balance. European Journal of Pharmacology, 405(1–3), 279–285.